About Us
CEO’s comment
NOV Summary
Key Members
Advisory Board
Scientific Advisory Board
Pipeline
Partnering
Partnering Models
Partners
Information
News
Press release
Contact Us
HOME
CONTACT US
SITEMAP
KOR
ENG
HOME
CONTACT US
SITEMAP
KOR
ENG
About Us
CEO’s comment
NOV Summary
Key Members
Advisory Board
Scientific Advisory Board
Pipeline
Partnering
Partnering Models
Partners
Information
News
Press release
Contact Us
search
home
Home
Government-Funded
Virtual Oncology Drug Development
Challenge for
Global Oncology
Drug Development
READ MORE
Government-Funded
Virtual Oncology Drug Development
Globally Competitive
Drug Pipeline
READ MORE
Government-Funded
Virtual Oncology Drug Development
Win Win
Partnering Model
READ MORE
1
2
3
Prev
Pause/Play
Next
About NOV
News
“Liquid Biopsy for Therapeutic Monitoring: New Area of Companion Diagnosti..
2018-10-10
more
Press release
TRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive Gl..
2018-12-05
more
NOV Pipeline
Product
Indication
Target
Nonclinical
Phase 1
Phase 2
NOV1105
Solid cancers (Ovarian, Melanoma)
HGF
NOV1201 (Licensed Out)
NSCLC, Breast cancer
Pan-HER
NOV1204
Solid tumors
Tubulin
NOV1301
HCC & MDS
ALK-5 (TGFβ type I receptor)
NOV1401
Solid tumors
PARP1/2
NOV1402
Solid tumors
PARP/TNKS
NOV1501 (Licensed Out)
Solid tumors
DLL4/VEGF
NOV1601
Solid tumors with TRK gene rearrangements or certain TRK mutations
Pan TRK
NOV1701
Solid tumors & Hematologic tumors
Myc
NOV1702
HPV-associated disease (CIN, cervical cancer)
E6 and E7 of HPV 16, 18 type
NOV1801
Solid tumors
4-1BB/TNFRSF9/CD137
NOV1802
Solid tumors
tumor-related multitargets
NOV1803
Solid tumors
CEACAM6 (CD66c)
: Antibody
: Small molecule
: Gene therapy
: Cell therapy
: etc